Chemerin As Potential Biomarker in Pediatric Diseases: A PRISMA-Compliant Study

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Mar 25

PMID 35327393

Authors

Katarzyna Zdanowicz

Anna Bobrus-Chociej

Dariusz Marek Lebensztejn

Affiliations

Soon will be listed here.

Abstract

Adipose tissue is the main source of adipokines and therefore serves not only as a storage organ, but also has an endocrine effect. Chemerin, produced mainly in adipocytes and liver, is a natural ligand for chemokine-like receptor 1 (CMKLR1), G-protein-coupled receptor 1 (GPR1) and C-C motif chemokine receptor-like 2 (CCRL2), which have been identified in many tissues and organs. The role of this protein is an active area of research, and recent analyses suggest that chemerin contributes to angiogenesis, adipogenesis, glucose homeostasis and energy metabolism. Many studies confirm that this molecule is associated with obesity in both children and adults. We conducted a systematic review of data from published studies evaluating chemerin in children with various disease entities. We searched PubMed to identify eligible studies published prior to February 2022. A total of 36 studies were selected for analysis after a detailed investigation, which was intended to leave only the research studies. Moreover, chemerin seems to play an important role in the development of cardiovascular and digestive diseases. The purpose of this review was to describe the latest advances in knowledge of the role of chemerin in the pathogenesis of various diseases from studies in pediatric patients. The mechanisms underlying the function of chemerin in various diseases in children are still being investigated, and growing evidence suggests that this adipokine may be a potential prognostic biomarker for a wide range of diseases.

Citing Articles

Adolescent obesity and ANGPTL8: correlations with high sensitivity C-reactive protein, leptin, and chemerin.

Hammad M, Channanath A, Abu-Farha M, Rahman A, Al Khairi I, Cherian P Front Endocrinol (Lausanne). 2024; 14:1314211.

PMID: 38189043 PMC: 10766807. DOI: 10.3389/fendo.2023.1314211.

The Role of Chemerin in Metabolic and Cardiovascular Disease: A Literature Review of Its Physiology and Pathology from a Nutritional Perspective.

Tan L, Lu X, Danser A, Verdonk K Nutrients. 2023; 15(13).

PMID: 37447205 PMC: 10343651. DOI: 10.3390/nu15132878.

The link between vitamin D, chemerin and metabolic profile in overweight and obese children - preliminary results.

Krajewska M, Witkowska-Sedek E, Ruminska M, Kucharska A, Stelmaszczyk-Emmel A, Sobol M Front Endocrinol (Lausanne). 2023; 14:1143755.

PMID: 37152969 PMC: 10159269. DOI: 10.3389/fendo.2023.1143755.

The Etiology of Cholelithiasis in Children and Adolescents-A Literature Review.

Zdanowicz K, Daniluk J, Lebensztejn D, Daniluk U Int J Mol Sci. 2022; 23(21).

PMID: 36362164 PMC: 9657413. DOI: 10.3390/ijms232113376.

Analysis of Sphingolipids in Pediatric Patients with Cholelithiasis-A Preliminary Study.

Zdanowicz K, Bobrus-Chcociej A, Pogodzinska K, Blachnio-Zabielska A, Zelazowska-Rutkowska B, Lebensztejn D J Clin Med. 2022; 11(19).

PMID: 36233480 PMC: 9570855. DOI: 10.3390/jcm11195613.

References

Kaur J, Mattu H, Chatha K, Randeva H . Chemerin in human cardiovascular disease. Vascul Pharmacol. 2018; 110:1-6. DOI: 10.1016/j.vph.2018.06.018. View

Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone S . Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases. Front Physiol. 2020; 11:578966. PMC: 7662468. DOI: 10.3389/fphys.2020.578966. View

Hoey H . Management of obesity in children differs from that of adults. Proc Nutr Soc. 2014; 73(4):519-25. DOI: 10.1017/S0029665114000652. View

Kennedy A, Davenport A . International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin) and GPR1 (Chemerin) Nomenclature, Pharmacology, and Function. Pharmacol Rev. 2017; 70(1):174-196. PMC: 5744648. DOI: 10.1124/pr.116.013177. View

Hamza R, Elkabbany Z, Shedid A, Hamed A, Ebrahim A . Serum Chemerin in Obese Children and Adolescents Before and After L-Carnitine Therapy: Relation to Nonalcoholic Fatty Liver Disease and Other Features of Metabolic Syndrome. Arch Med Res. 2017; 47(7):541-549. DOI: 10.1016/j.arcmed.2016.11.010. View

Helfer G, Wu Q . Chemerin: a multifaceted adipokine involved in metabolic disorders. J Endocrinol. 2018; 238(2):R79-R94. PMC: 6026924. DOI: 10.1530/JOE-18-0174. View

Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M . Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol. 1997; 109(1):91-5. DOI: 10.1111/1523-1747.ep12276660. View

Estienne A, Bongrani A, Reverchon M, Rame C, Ducluzeau P, Froment P . Involvement of Novel Adipokines, Chemerin, Visfatin, Resistin and Apelin in Reproductive Functions in Normal and Pathological Conditions in Humans and Animal Models. Int J Mol Sci. 2019; 20(18). PMC: 6769682. DOI: 10.3390/ijms20184431. View

Treeck O, Buechler C . Chemerin Signaling in Cancer. Cancers (Basel). 2020; 12(11). PMC: 7690612. DOI: 10.3390/cancers12113085. View

10.

Hillenbrand A, Weiss M, Knippschild U, Wolf A, Huber-Lang M . Sepsis-Induced Adipokine Change with regard to Insulin Resistance. Int J Inflam. 2012; 2012:972368. PMC: 3261472. DOI: 10.1155/2012/972368. View

11.

Maghsoudi Z, Kelishadi R, Hosseinzadeh-Attar M . The comparison of chemerin, adiponectin and lipid profile indices in obese and non-obese adolescents. Diabetes Metab Syndr. 2016; 10(2 Suppl 1):S43-6. DOI: 10.1016/j.dsx.2016.01.020. View

12.

Rourke J, Dranse H, Sinal C . CMKLR1 and GPR1 mediate chemerin signaling through the RhoA/ROCK pathway. Mol Cell Endocrinol. 2015; 417:36-51. DOI: 10.1016/j.mce.2015.09.002. View

13.

Suhett L, Hermsdorff H, Ribeiro S, Filgueiras M, Shivappa N, Hebert J . The dietary inflammatory index is associated with anti- and pro-inflammatory adipokines in Brazilian schoolchildren. Eur J Nutr. 2021; 60(5):2841-2849. DOI: 10.1007/s00394-021-02500-8. View

14.

Klusek-Oksiuta M, Bialokoz-Kalinowska I, Tarasow E, Wojtkowska M, Werpachowska I, Lebensztejn D . Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children. Ital J Pediatr. 2014; 40:84. PMC: 4237733. DOI: 10.1186/s13052-014-0084-4. View

15.

De Henau O, Degroot G, Imbault V, Robert V, De Poorter C, Mcheik S . Signaling Properties of Chemerin Receptors CMKLR1, GPR1 and CCRL2. PLoS One. 2016; 11(10):e0164179. PMC: 5055294. DOI: 10.1371/journal.pone.0164179. View

16.

Vos M, Abrams S, Barlow S, Caprio S, Daniels S, Kohli R . NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology.... J Pediatr Gastroenterol Nutr. 2017; 64(2):319-334. PMC: 5413933. DOI: 10.1097/MPG.0000000000001482. View

17.

Jacenik D, Fichna J . Chemerin in immune response and gastrointestinal pathophysiology. Clin Chim Acta. 2020; 504:146-153. DOI: 10.1016/j.cca.2020.02.008. View

18.

Wojcik M, Koziol-Kozakowska A, Janus D, Furtak A, Malek A, Sztefko K . Circulating chemerin level may be associated with early vascular pathology in obese children without overt arterial hypertension - preliminary results. J Pediatr Endocrinol Metab. 2020; 33(6):729-734. DOI: 10.1515/jpem-2019-0460. View

19.

Du X, Zabel B, Myles T, Allen S, Handel T, Lee P . Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem. 2008; 284(2):751-8. PMC: 2613638. DOI: 10.1074/jbc.M805000200. View

20.

Ba H, Xu L, Qin Y, Chen H . Serum Chemerin Levels Correlate With Determinants of Metabolic Syndrome in Obese Children and Adolescents. Clin Med Insights Pediatr. 2019; 13:1179556519853780. PMC: 6557013. DOI: 10.1177/1179556519853780. View